This study will investigate whether digital nudge letters delivered via the official Danish electronic letter system directly to patients with CKD and their associated GPs will improve GDMT in patients with CKD when compared to no letters. conditions: Chronic Kidney Diseases conditions: Behavior and Behavior Mechanisms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: 2x2 factorial design primaryPurpose: OTHER masking: NONE count: 35000 type: ESTIMATED name: Electronically delivered nudging letters to patients with CKD name: Electronically delivered nudging letter to associated GPs of patients with CKD measure: Number of participants with any prescription of renin-angiotensin system inhibition and/or sodium-glucose cotransporter 2 inhibitors measure: Number of participants with any prescription of renin-angiotensin system inhibition measure: Number of participants with any prescription of sodium-glucose cotransporter 2 inhibitors measure: Number of participants with a new prescription of renin-angiotensin system inhibition and/or sodium-glucose cotransporter 2 inhibitors measure: Number of participants with a new prescription of renin-angiotensin system inhibition measure: Number of participants with a new prescription of sodium-glucose cotransporter 2 inhibitors measure: Time from intervention delivery to a new prescription of renin-angiotensin system inhibition and/or sodium-glucose cotransporter 2 inhibitors measure: Time from intervention delivery to a new prescription of renin-angiotensin system inhibition measure: Time from intervention delivery to a new prescription of sodium-glucose cotransporter 2 inhibitors measure: Number of participants with an increase in baseline daily RASi dosage measure: Number of participants with any prescription of mineralocorticoid receptor antagonists measure: Number of participants with any prescription of non-steroid mineralocorticoid receptor antagonists measure: Number of participants with any prescription of cholesterol-lowering medication measure: Number of participants with any prescription of glucagon-like peptide-1 analogue measure: Number of participants with any prescription of antidiabetic medication besides SGLT2i measure: Number of participants with any prescription of antidiabetic medication measure: Number of participants with any prescription of antihypertensive medication besides renin-angiotensin system inhibition measure: Number of participants with any prescription of antihypertensive medication measure: Number of participants with a new prescription of mineralocorticoid receptor antagonists measure: Number of participants with a new prescription of non-steroid mineralocorticoid receptor antagonists measure: Number of participants with a new prescription of cholesterol-lowering medication measure: Number of participants with a new prescription of glucagon-like peptide-1 analogue measure: Number of participants with a new prescription of antidiabetic medication besides sodium-glucose cotransporter 2 inhibitors measure: Number of participants with a new prescription of antidiabetic medication measure: Number of participants with a new prescription of antihypertensive medication besides renin-angiotensin system inhibition measure: Number of participants with a new prescription of antihypertensive medication measure: Change in number of antihypertensive medications measure: Number of participants referred to nephrology outpatient clinics measure: Number of participants with an assessment of urine albumine to creatine ratio measure: Number of participants with an assessment of plasma-creatinine. measure: Number of participants with an assessment of estimated glomerular filtration rate by creatinine measure: Number of participants with an assessment of hemoglobin A1c measure: Number of participants with an assessment of lipids measure: Number of participants recipient of influenza vaccination measure: Number of participants recipient of COVID-19 vaccination measure: Total number of visits to general practitioners measure: Time to first phone contact to a general practice measure: Time to first visit with a general practitioner measure: Number of participants with any prescription of renin-angiotensin system inhibition and/or sodium-glucose cotransporter 2 inhibitors measure: Number of participants with any prescription of renin-angiotensin system inhibition measure: Number of participants with any prescription of sodium-glucose cotransporter 2 inhibitors measure: Number of participants with a new prescription of renin-angiotensin system inhibition and/or sodium-glucose cotransporter 2 inhibitors measure: Number of participants with a new prescription of renin-angiotensin system inhibition measure: Number of participants with a new prescription of sodium-glucose cotransporter 2 inhibitors measure: Time from intervention delivery to prescription of renin-angiotensin system inhibition and/or sodium-glucose cotransporter 2 inhibitors measure: Time from randomization to prescription of renin-angiotensin system inhibition measure: Time from randomization to prescription of sodium-glucose cotransporter 2 inhibitors measure: Number of participants who have discontinued renin-angiotensin system inhibition treatment. measure: Number of participants who have discontinued sodium-glucose cotransporter 2 inhibition treatment. measure: Rate of change in estimated glomerular filtration rate measure: Rate of change in urine albumine to creatinine ratio measure: Number of participants with any hospitalization measure: Total number of all-cause hospitalizations measure: All-cause mortality measure: Number of participants with kidney failure defined as a composite of sustained estimated glomerular filtration rate <15ml/min/1.73m2, dialysis dependence and kidney transplantation measure: Number of participants with kidney failure (alternative definition #1) defined as a composite of sustained estimated glomerular filtration rate <15ml/min/1.73m2, dialysis dependence, kidney transplantation and renal death measure: Number of participants with kidney failure (alternative definition #2) defined as a composite of sustained estimated glomerular filtration rate <15ml/min/1.73m2, dialysis dependence, kidney transplantation, renal death, and cardiovascular death. measure: Number of participants with acute dialysis measure: Number of participants with acute kidney insufficiency measure: Number of participants with incident heart failure, heart failure hospitalization, or cardiovascular death measure: Number of participants with major adverse cardiovascular events defined as a composite of myocardial infarction, stroke, and cardiovascular death. measure: Number of participants with major adverse cardiovascular events (alternative definition) defined as a composite of myocardial infarction, revascularization, stroke, and cardiovascular death. measure: Number of participants with individual components of the renal/cardiovascular composite outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte city: Hellerup state: Hovedstaden zip: 2900 country: Denmark lat: 55.73204 lon: 12.57093 hasResults: False